Progen's distribution arm picks up new agencies

By Pete Young
Wednesday, 03 April, 2002

Brisbane-based biotech Progen Industries has been appointed exclusive Australian distributor for two product ranges used by lab researchers.

Progen will distribute Pierce and Endogen brands through its life sciences division, which distributes biological and chemical research products in Australia and New Zealand.

The agreeement should help finance the main thrust of Progen's business which is centered around R&D activity related to its lead anti-cancer drug candidate PI-88 now in clinical trials.

Progen's life sciences division forms part of its commercial services unit, which last financial year generated more than $2.4 million and has already posted a 46 per cent rise in revenues this year. The unit also contract-manufactures potential therapeutics and vaccines under Good Manufacturing Standards (GMP).

Pierce products are used by researchers in protein chemistry, immunology and molecular biology. Endogen is a major supplier of compounds related to the measurement of cytokines and chemokines (the chemical messengers of the immune system).

Related News

Anti-inflammatory agent could decrease septic shock mortality

Researchers have discovered a naturally occurring blood protein — a type of...

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd